Navitoclax displayed strong efficacy against a range of cancers with high levels of BCL-2 and BCL-xL expression, most notably chronic lymphocytic leukemia (CLL), and lymphomas [22]. The gene discussed is BCL2L1; the disease is B-cell chronic lymphocytic leukemia.